DK0470128T3 - Aktive polyalkylenoxidcarbonater til modifikation af polypeptider - Google Patents

Aktive polyalkylenoxidcarbonater til modifikation af polypeptider

Info

Publication number
DK0470128T3
DK0470128T3 DK90906698T DK90906698T DK0470128T3 DK 0470128 T3 DK0470128 T3 DK 0470128T3 DK 90906698 T DK90906698 T DK 90906698T DK 90906698 T DK90906698 T DK 90906698T DK 0470128 T3 DK0470128 T3 DK 0470128T3
Authority
DK
Denmark
Prior art keywords
polypeptides
modification
polyalkylene oxide
peg
oxide carbonates
Prior art date
Application number
DK90906698T
Other languages
English (en)
Other versions
DK0470128T4 (da
Inventor
Shmuel Zalipsky
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23335516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0470128(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of DK0470128T3 publication Critical patent/DK0470128T3/da
Application granted granted Critical
Publication of DK0470128T4 publication Critical patent/DK0470128T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
DK90906698T 1989-04-19 1990-04-19 Aktive polyalkylenoxidcarbonater til modifikation af polypeptider DK0470128T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34092889A 1989-04-19 1989-04-19
PCT/US1990/002133 WO1990013540A1 (en) 1989-04-19 1990-04-19 Active carbonates of polyalkylene oxides for modification of polypeptides

Publications (2)

Publication Number Publication Date
DK0470128T3 true DK0470128T3 (da) 2000-01-10
DK0470128T4 DK0470128T4 (da) 2003-12-01

Family

ID=23335516

Family Applications (2)

Application Number Title Priority Date Filing Date
DK90906698T DK0470128T4 (da) 1989-04-19 1990-04-19 Aktive polyalkylenoxidcarbonater til modifikation af polypeptider
DK98203166T DK0893439T3 (da) 1989-04-19 1990-04-19 Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98203166T DK0893439T3 (da) 1989-04-19 1990-04-19 Fremgangsmåde til fremstilling af et modificeret polypeptid indeholdende et polypeptid og et polyalkylenoxid

Country Status (10)

Country Link
EP (2) EP0893439B1 (da)
JP (1) JP2875884B2 (da)
AT (2) ATE300519T1 (da)
AU (1) AU5526690A (da)
CA (1) CA2053317C (da)
DE (2) DE69033192T3 (da)
DK (2) DK0470128T4 (da)
ES (2) ES2247656T3 (da)
HU (1) HUT64022A (da)
WO (1) WO1990013540A1 (da)

Families Citing this family (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
CA2101918A1 (en) * 1991-03-18 1992-09-19 Samuel Zalipsky Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2101361A1 (en) * 1992-08-27 1994-02-28 Robert A. Snow Low diol polyalkylene oxide biologically active proteinaceous substances
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5583114A (en) * 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
WO1996040792A1 (en) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
WO1996040791A1 (en) * 1995-06-07 1996-12-19 Novo Nordisk A/S Modification of polypeptides
US6818018B1 (en) 1998-08-14 2004-11-16 Incept Llc In situ polymerizable hydrogels
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2001051510A2 (en) 2000-01-10 2001-07-19 Maxygen Holdings Ltd G-csf conjugates
WO2001058935A2 (en) 2000-02-11 2001-08-16 Maxygen Aps FACTOR VII OR VIIa-LIKE MOLECULES
WO2001060335A2 (en) 2000-02-17 2001-08-23 3M Innovative Properties Company Delivery systems using preformed biodegradable polymer compositions and methods
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
EP2322229B1 (en) 2001-10-10 2016-12-21 Novo Nordisk A/S Remodeling and glycoconjugation of Factor IX
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
DK1578771T3 (da) 2001-10-10 2013-06-10 Novo Nordisk As Remodellering og glycokonjugering af peptider
NZ536340A (en) 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
ES2363205T3 (es) 2002-06-21 2011-07-26 Novo Nordisk Health Care Ag Glicoformas del factor vii pegilado.
US8034900B2 (en) 2002-12-30 2011-10-11 Amylin Pharmaceuticals, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
NZ542094A (en) 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
SG155777A1 (en) 2003-04-09 2009-10-29 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP1624847B1 (en) 2003-05-09 2012-01-04 BioGeneriX AG Compositions and methods for the preparation of human growth hormone glycosylation mutants
GB0314472D0 (en) * 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
CA2542179A1 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Il-21 derivatives
EP2633866A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7842661B2 (en) 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP1765853B1 (en) 2004-01-08 2015-10-28 ratiopharm GmbH O-linked glycosylation of G-CSF peptides
US8778880B2 (en) 2004-02-02 2014-07-15 Ambrx, Inc. Human growth hormone modified at position 35
ZA200609638B (en) * 2004-04-21 2008-02-27 Alza Corp Polymer conjugate releasable under mild thiolytic conditions
ZA200609930B (en) 2004-06-08 2009-01-28 Alza Corp Macromolecular peg conjucates by four-component condensation
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
AU2005322019B2 (en) 2004-12-22 2010-08-26 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
DK2399893T3 (da) 2004-12-22 2018-10-08 Ambrx Inc Sammensætninger indeholdende, fremgangsmåder der involverer, og anvendelser af ikke-naturlige aminosyrer og polypeptider
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
JP2008534640A (ja) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー タンパク質の機能部位またはエピトープの遮蔽方法
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1893229B1 (en) 2005-06-03 2011-10-19 Ambrx, Inc. Improved human interferon molecules and their uses
JP5335422B2 (ja) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP1797901A1 (en) 2005-12-16 2007-06-20 Diatos Cell penetrating peptide conjugates for delivering nucleic acids into cells
RU2470940C2 (ru) 2006-03-13 2012-12-27 Лиат МИНТЦ Применение варианта сплайсинга грелина для лечения кахексии, и/или анорексии, и/или анорексии-кахексии, и/или нарушения питания, и/или липодистрофии, и/или мышечного истощения, и/или стимуляции аппетита
EP2029738A2 (en) 2006-05-24 2009-03-04 Novo Nordisk Health Care AG Factor ix analogues having prolonged in vivo half life
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP5840345B2 (ja) 2006-09-08 2016-01-06 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾ヒト血漿ポリペプチドまたは修飾ヒトＦｃ足場タンパク質ならびにこれらの利用
KR20090051227A (ko) 2006-09-08 2009-05-21 암브룩스, 인코포레이티드 척추동물 세포를 위한 하이브리드 서프레서 ｔＲＮＡ
AU2007292893B2 (en) 2006-09-08 2012-03-01 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
MX2009003470A (es) 2006-10-04 2009-04-14 Novo Nordisk As Azucares y glicopeptidos pegilados enlazados a glicerol.
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
NZ580030A (en) 2007-04-03 2012-06-29 Biogenerix Ag Methods of treatment using glycopegylated g-csf
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
JP5547083B2 (ja) 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
NZ620606A (en) 2008-02-08 2015-08-28 Ambrx Inc Modified leptin polypeptides and their uses
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
US9040723B2 (en) * 2008-07-14 2015-05-26 Biocon Limited Method of synthesizing a substantially monodispersed mixture of oligomers
PE20110426A1 (es) 2008-07-23 2011-07-01 Ambrx Inc Polipeptidos g-csf bovinos modificados
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CA2784793A1 (en) 2009-12-21 2011-07-21 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
US20120135912A1 (en) 2010-05-10 2012-05-31 Perseid Therapeutics Llc Polypeptide inhibitors of vla4
EP2605789B1 (en) 2010-08-17 2019-06-05 Ambrx, Inc. Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CN103429256B (zh) 2011-03-02 2022-09-13 诺和诺德保健股份有限公司 凝血因子向活化的血小板上的tlt-1的靶向
US9051562B2 (en) 2011-06-15 2015-06-09 Institut National De La Santé Et De La Recherche Médicale (Inserm) Polypeptides isolated from brevibacterium aurantiacum and their use for the treatment of cancer
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP3088005B1 (en) 2011-07-05 2019-01-02 biOasis Technologies Inc P97-antibody conjugates
JP6262206B2 (ja) 2012-05-01 2018-01-17 ノヴォ ノルディスク アー／エス 医薬組成物
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
EP3135690A1 (en) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
CN104981254B (zh) 2012-08-31 2018-05-22 苏特罗生物制药公司 含有叠氮基的经修饰的氨基酸
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
JP2016505528A (ja) 2012-11-16 2016-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質の化学修飾のためのピクテ−スペングラーライゲーション
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
JP6586016B2 (ja) 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015031673A2 (en) 2013-08-28 2015-03-05 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
CN105744935B (zh) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
WO2017029391A1 (en) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) New method for treating cancer
EP4019007A1 (en) 2016-06-01 2022-06-29 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
MA46568A (fr) 2016-10-24 2019-08-28 Novo Nordisk As Dosage biologique de formulations d'insuline
AU2018219283B2 (en) 2017-02-08 2022-05-19 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019038420A1 (en) 2017-08-25 2019-02-28 INSERM (Institut National de la Santé et de la Recherche Médicale) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OSTEOCLAST DISEASES
WO2019133399A1 (en) 2017-12-26 2019-07-04 Becton, Dickinson And Company Deep ultraviolet-excitable water-solvated polymeric dyes
JP2021519841A (ja) 2018-03-30 2021-08-12 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ ペンダントクロモフォアを有する水溶性ポリマー色素
WO2020023300A1 (en) 2018-07-22 2020-01-30 Bioasis Technologies, Inc. Treatment of lymmphatic metastases
FI3849614T3 (fi) 2018-09-11 2024-02-08 Ambrx Inc Interleukiini-2-polypeptidikonjugaatteja ja niiden käyttöjä
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
WO2021048171A1 (en) 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
CA3177039A1 (en) 2020-12-28 2022-07-07 Davol Inc. Reactive dry powdered hemostatic materials comprising a protein and a multifunctionalized modified polyethylene glycol based crosslinking agent
WO2022152698A1 (en) 2021-01-12 2022-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of npdk-d to evaluate cancer prognosis
WO2022200469A1 (en) 2021-03-24 2022-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) A dominant negative protein of rad51 for treating cancer
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2631656C2 (de) * 1976-07-14 1983-02-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung eines Hydroxysuccinimidoester-Derivats zur Bindung von biologisch aktiven Proteinen aneinander und/oder an flüssige oder feste Trägerstoffe
CS204190B1 (en) † 1978-02-22 1981-03-31 Jaroslav Drobnik Activation method for hydrxyl groups containing insoluble carriers
YU144584A (en) † 1983-08-25 1987-06-30 Akad Wissenschaften Ddr Process for making n-(chlorocarbonyloxi)-s-norbornen-2,3-dicarboximide
DD219490A1 (de) † 1983-10-28 1985-03-06 Akad Wissenschaften Ddr Verfahren zur herstellung aktivierter traeger
JPS60156395A (ja) * 1984-01-17 1985-08-16 Mihama Hisaharu 修飾リパーゼ
DE3413904A1 (de) * 1984-04-13 1985-10-24 Hoechst Ag, 6230 Frankfurt Polymerisate auf basis von polyvinylencarbonat und/oder polyhydroxymethylen, verfahren zu ihrer herstellung und ihre anwendung
FR2574075B1 (fr) * 1984-12-04 1987-09-18 Poudres & Explosifs Ste Nale Procede de synthese d'esters actifs d'acides carboxyliques, nouveaux carbonates alpha-halogenes utiles pour cette synthese et leur mode d'obtention
JPH0757760B2 (ja) * 1987-06-05 1995-06-21 宇部興産株式会社 生体由来物質の固定化方法
DD260701A1 (de) † 1987-06-30 1988-10-05 Akad Wissenschaften Ddr Verfahren zur umesterung von aktiven unsymmetrischen kohlensaeurediester-gruppen an hydroxylgruppenhaltigen polymeren
DD261791A1 (de) † 1987-06-30 1988-11-09 Akad Wissenschaften Ddr Verfahren zur herstellung von carbonaten hydroxylgruppenhaltiger polymere
IE64284B1 (en) † 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1

Also Published As

Publication number Publication date
DE69033192D1 (de) 1999-08-05
DE69034200D1 (de) 2005-09-01
WO1990013540A1 (en) 1990-11-15
DE69034200T2 (de) 2006-05-24
DK0893439T3 (da) 2005-09-05
JPH04504872A (ja) 1992-08-27
ATE181732T1 (de) 1999-07-15
EP0470128A4 (en) 1992-09-16
EP0470128B2 (en) 2003-08-13
CA2053317A1 (en) 1990-10-20
DE69033192T3 (de) 2004-05-19
HU903628D0 (en) 1991-12-30
ES2136595T3 (es) 1999-12-01
CA2053317C (en) 1996-03-12
EP0893439B1 (en) 2005-07-27
EP0470128A1 (en) 1992-02-12
ES2136595T5 (es) 2004-04-01
EP0893439A1 (en) 1999-01-27
JP2875884B2 (ja) 1999-03-31
ATE300519T1 (de) 2005-08-15
EP0470128B1 (en) 1999-06-30
DK0470128T4 (da) 2003-12-01
DE69033192T2 (de) 2000-03-09
AU5526690A (en) 1990-11-29
HUT64022A (en) 1993-11-29
ES2247656T3 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
DK0470128T3 (da) Aktive polyalkylenoxidcarbonater til modifikation af polypeptider
ATE424431T2 (de) Verfahren zur herstellung von 1- benzotriazolcarbonatestern von wasserlöslichen polymeren
DE69521901T2 (de) Spritzgegossene darreichungsform
DK0682944T3 (da) Stabil, lyofiliseret, proteinholdig formulering og doseringskit
NO990560D0 (no) Kjemisk modifiserte polypeptider
OA09760A (fr) "Conjugués de protéine et de polyéthylène glycol".
ES2124685T3 (es) Variantes del inhibidor de la tripsina pancreatica bovina, su produccion y uso.
RU2002120486A (ru) Свободная от агрегатов уратоксидаза для приготовления неиммуногенных полимерных конъюгатов
EP0372752A3 (en) Cd4 polypeptide derivatives
DE69126568T2 (de) Neues physiologisch aktives Schweinepeptid (CNP-53)
WO2004011524A3 (en) Sulfonated aliphatic-aromatic copolyetheresters
FI862821A0 (fi) Monoklonala antikroppar och antigener foer humana icke-litencellslungcancer.
EP0331356A3 (en) Expression of hiv binding proteins
FI905825A0 (fi) Amfifiliska peptider och deras anvaendning.
ATE346096T1 (de) G-csf tpo fusionsproteine
NO911557L (no) Fremgangsmaate for fremstilling av fremmedproteiner i streptomyceter.
ES2144392T3 (es) Vectores de expresion para la sintesis de proteinas en la levadura de escision schizosaccharomyces pombe.
DK0490383T3 (da) Peptider af HIV-gag-proteinet, fremstilling og anvendelse deraf
DE50009177D1 (de) Proteinhaltige Hydrogele
CA2088478A1 (en) Cloning and expression of a rhoptry associated protein of p. falciparum
FI870501A0 (fi) Menetelmä melanoomaan liittyvän p97-antigeenin antigeenisen sukulaispeptidin tai -proteiinin valmistamiseksi, sekä siinä käyttökelpoiset yhdistelmävirukset, yhdistelmävektorit ja isäntäsolut
ES2129022T3 (es) Proteina condromodulina-i.
FR2661188B1 (fr) Nouveaux vecteurs de clonage et/ou d'expression, procede de preparation et leur utilisation.
ATE81531T1 (de) Biologisch aktive peptide tan-866.